ReviewNature reviews. Urology2026
Puberty suppression and sexual well-being in transgender and gender-diverse individuals: evidence- and experience-based counselling and future research directions.
Review in Nature reviews. Urology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Despite its increasing clinical use, evidence regarding the effects of puberty suppression using gonadotropin-releasing hormone analogues on sexual development and well-being in transgender and gender-diverse (TGD) adolescents remains limited. Thus, expert recommendations integrating available evidence and clinical experience are essential to guide multidisciplinary care. Targeted literature review coupled with expert opinion - including endocrine, urological, psychological, sexological and gynaecological perspectives - and input from a round table session at the European Professional Association for Transgender Health Conference in 2025, generated recommendations around providing developmentally appropriate information on puberty, puberty suppression and sexual development. These include attention to psychosocial factors such as stigma; individualized decision making regarding fertility and surgical options; and promotion of positive communication about sexuality. Remaining knowledge gaps emphasize the need for longitudinal and interdisciplinary research, combining qualitative and quantitative approaches to advance our understanding of sexual development during puberty suppression, and how it affects sexual pleasure and genital sensitivity. The first exploratory studies have shown similar sexual well-being in young adults who received puberty suppression and those who received gender-affirming hormone treatment without puberty suppression. Another priority is the development of TGD-specific tools to assess sexual development, functioning and satisfaction, that capture the diversity and intersectionality of sexual experiences of TGD individuals. These recommendations aim to support individuals considering puberty suppression and their families and clinicians to optimize their care and well-being.
Identifiers
42687008What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.